Nuvectis Pharma, Inc. 8-K

What Happened
Nuvectis Pharma, Inc. (NVCT) filed an 8‑K on June 29, 2026 reporting it has reduced the amount available for sales under its Sales Agreement Prospectus to $5.0 million and has suspended that prospectus. The Company originally entered the Sales Agreement with Leerink Partners LLC on May 9, 2025. While the Sales Agreement remains in effect, Nuvectis will not sell shares under the current prospectus unless and until a new prospectus, prospectus supplement, or registration statement is filed.

Key Details

• Agreement date: Sales Agreement with Leerink Partners LLC was entered on May 9, 2025.
• New cap: Amount available for sales under the prospectus lowered to $5.0 million (effective June 29, 2026).
• Suspension: The Company has suspended the Sales Agreement Prospectus and will not make sales under it until a new prospectus/prospectus supplement or registration statement is filed.
• Agreement status: The underlying Sales Agreement itself remains in full force and effect.

Why It Matters
This action limits Nuvectis’s immediate ability to raise capital through sales of common stock under the existing prospectus. For investors, it means the company has temporarily halted at‑will share offerings under this specific prospectus until new disclosure is filed, which could affect near‑term dilution risk and the company’s access to equity financing. Watch future SEC filings for any new prospectus, prospectus supplement, or registration statement that would reopen or change the offering.